Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: A review of the literature and possible mechanisms

Journal of Forensic Sciences

Volumn 42, Issue 2, 1997, Pages 335-339

  Robert Swanson, J ^a,c   Jones, Graham R ^a   Krasselt, Wendell ^a,b   Denmark, Lloyd N ^a,b   Ratti, Frank ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Office of the Chief Medical Examiner   (Canada)

^c Lane County Medical Examiners Office ^*  (United States)

Author keywords

accumulation; chlorpromazine; CYP2D6; cytochrome P450; desipramine; fast metabolizer; forensic science; forensic toxicology; imipramine; isozyme; metabolism; n euroleptic; phenothiazine; phenotype; polymorphism; postmortem; redistribu tion; slow metabolizer; thioridazine

Indexed keywords

DESIPRAMINE; DRUG METABOLITE; IMIPRAMINE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CHILD; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; FEMALE; HUMAN; LONG TERM CARE; MALE; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; SUDDEN DEATH;

EID: 0031041509     PISSN: 00221198     EISSN: None     Source Type: Journal    
DOI: 10.1520/jfs14124j     Document Type: Article

References (41)

1. Biederman J, Gastfriend DR, Jellinek MS. Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 1986;6:359-63.
2. Donnelly M, Zametkin AJ, Rapoport JL, Ismond DR, Weingartner H, Lane E, et al. Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 1986;39:72-81.
3. Popper CW. Child psychiatry: Pharmacotherapy. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1995;2418-427.
4. Strober M. The pharmacotherapy of depressive illness in adolescence: III. Diagnostic and conceptual issues in studies of tricyclic antidepressants. J Child Adolescent Psychopharmacol 1992;2(1): 23-9.
5. Preskom SH, Bupp SJ, Weller EB, Weller RA. Plasma levels of imipramine and metabolites in 68 hospitalized children. J Amer Acad Child Adolesc Psychiatr 1989;28(3):373-5.
6. Preskorn SH, Weller E, Jerkovich G, Hughes CW, Weller R. Depression in children: Concentration-dependent CNS toxicity of tricyclic antidepressants. Psychopharmacol Bull 1988;24:140-2.
7. Hammer W, Sjoqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sei 1967;6:1895-903.
8. Apple FS. Postmortem tricyclic antidepressant concentrations: Assessing cause of death using parent drug to metabolite ratio. J AnalToxicol 1989;13:197-8.
9. Apple FS, Bandt CM. Liver and blood postmortem tricyclic antidepressant concentrations. Am J Clin Pathol 1988;89:794-6.
10. Prouty RW, Anderson WH. The forensic science implications of site and temporal influences on postmortem blood-drug concentrations. J Forensic Sei 1990;35(2):243-70.
11. Jones GR, Pounder DJ. Site dependence of drug concentrations in postmortem blood-A case study. J Anal Toxicol 1987;! 1:186-90.
12. Hanzlick R. Postmortem tricyclic antidepressant concentrations, lethal versus nonlethal levels. Am J Forensic Med Pathol 1989; 10(4):326-9.
13. Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man. 4th ed. Foster City, CA: Chemical Toxicology Institute, 1995; 392-5.
14. Bailey DN, Van Dyke C, Langou RA, Jatlow PI. Tricyclic antidepressant: Plasma levels and clinical findings in overdose. Am J Psychiatry I978;135(ll):1325-8.
15. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36: 537-47.
16. Su P, Coutts RT, Baker GB, Daneshtalab M. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica 1993;23(ll):1289-98.
17. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43(5):827-32.
18. Brosen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991;49(6):609-17.
19. Skjelbo E, Brosen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
20. Koyama E, Sohn D, Shin S, Chiba K, Shin J, Kim Y, et al. Metabolic disposition of imipramine in oriental subjects: Relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. J Pharmacol Exp Ther 1994;271(2):860-7.
21. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994;37:237-42.
22. Brosen K. Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18(3):22Q-39.
23. Brosen K, Gram LF, Klysner R, Bech P. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986:30:43-9.
24. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679-84.
25. Lennard MS. Genetically determined adverse drug reactions involving metabolism. Drug Safety 1993;9(l):60-77.
26. Spina E, Marlines C, Caputi AP, Cobaleda J, Pinas B. Debrisoquine oxidation phenotype during neuroleptic therapy. Eur J Clin Pharmacol 1991;41:467-70.
27. Von Bahr C, Spina E, Birgersson C, Ericsson O, Goransson M, Henthorn T, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985;34(14):2501-5.
28. Messiha FS. Fluoxetine: Adverse effects and drug-drug interactions. Clin Toxicol 1993;31(4):603-30.
29. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990;10(1):48-50.
30. Jortani SA, Poklis A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J Anal Toxicol 1993;17(6):374-7.
31. Axelsson R, Martensson E. Serum concentration and elimination from serum of thioridazine in psychiatric patients. Curr Ther Res 1976;19(2):242-65.
32. Von Bahr C, Movin G, Nordin C, Liden A, Harrarlund-Udenaes M, Hedberg A, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-40.
33. Inaba T, Otton SV, Kalow W. Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther 1980;27(4):547-9.
34. Geller B, Cooper TB, Farooki ZQ, Chestnut EC. Dose and plasma levels of nortriptyline and chlorpromazine in delusionally depressed adolescents and of nortriptyline in nondelusionally depressed adolescents. Am J Psychiatry 1985;142(3):336-8.
35. Laposata EA, Hale P, Poklis A. Evaluation of sudden death in psychiatric patients with special reference to phenothiazine therapy: Forensic pathology. J Forensic Sei 1988;33(2):432-40.
36. Di Maio DJ, Di Maio VJM. Forensic pathology. New York: Elsevier, 1989;1-503.
37. Popper C, Elliott GR. Postmortem pharmacokinetics of tricyclic antidepressants: Are some deaths during treatment misattributed to overdose? J Child Adolescent Psychopharmacol 1993;3(l):x-xii.
38. Popper CW, Zimnitzky B. Sudden death putatively related to desipramine in youth: A fifth case and a review of speculative mechanisms. J Child Adolescent Psychopharmacol 1995;5(4):283-300.
39. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Amer Acad Child Adolesc Psychiatr 1991;30:104-8.
40. Sudden death in children treated with tricyclic antidepressants [editorial]. Med Lett Drugs Ther 1990;32:53-4.
41. Additional information and reprint requests: J. Robert Swanson, Ph.D. Pathology Department, L471 Oregon Health Sciences University Portland, OR 97201